Gain Therapeutics announced encouraging Phase 1b clinical trial results for rexaceract, its lead drug candidate for Parkinson's disease, showing safety, tolerability, and early signs of efficacy. The FDA has authorized the Investigational New Drug (IND) application, enabling the company to start a Phase 2 study in Q3 2026 across the US, Australia, and Europe. Rexaceract targets disease modification by restoring enzyme function linked to Parkinson's progression, with biomarker improvements supporting its mechanism. The company also promoted key executives and is advancing a second candidate, GT-04686, toward clinical development.
Aduro Clean Technologies and ECOCE have successfully completed Phase 1 of mapping flexible and multilayer plastic waste streams in Mexico, estimated at 1.5 million tons annually. The project now moves into testing these materials using Aduro's Hydroc...
Aduro Clean Technologies and ECOCE have completed phase 1 of mapping flexible plastic waste streams in Mexico, estimated at 1.5 million tonnes annually. They are now moving selected post-consumer flexible packaging materials into Hydrochemolytic™ (HC...
Camurus announced that the US FDA has accepted the resubmission of the New Drug Application (NDA) for CAM2029, an extended-release octreotide injection for treating acromegaly. The FDA set a Prescription Drug User Fee Act (PDUFA) target action date o...
Sea Limited reported strong Q1 2026 results with revenue exceeding $7 billion, up 47% year-over-year, driven by its integrated business model spanning e-commerce (Shopee), financial services (Monee), and gaming (Garena). The company achieved adjusted...
Whale Alert detected a large transfer of 55 million USDT stablecoins to Binance via the Tron network. Such significant stablecoin inflows to major exchanges like Binance often indicate potential trading activity or liquidity positioning, though the e...
